Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Robot vs. laparoscopic surgery: which is better for adrenal removal?

NCT ID NCT05853302

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study looked back at 316 patients who had surgery to remove an adrenal gland. It compared robot-assisted surgery to standard laparoscopic surgery to see which was safer, more effective, and more cost-effective. The goal was to help doctors choose the best approach for patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

316 people

The number who actually took part.

Started

Dec 2022

Finished

Sep 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

In consideration of the 15%-minimally invasive procedure-related morbidity rate (both with laparoscopic and robotic approach), the 5%-significativity, the 80%-study power and the 10%-non-inferiority limit, the sample size is 316 patients. Such sample size is divided in 15 patients per group (Sealed Envelope Ltd. 2012. Power calculator for binary outcome noninferiority trial. \[Online\] Available from: https://www.sealedenvelope.com/power/binary-noninferior/ \[Accessed Mon Jan 31 2022\]).

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patients who underwent minimally-invasive unilateral adrenalectomy with lateral transabdominal approach between June 1st 1997 and December 31st 2021 Exclusion Criteria: Patients who underwent bilateral or retroperitoneoscopic adrenalectomy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adrenalectomy; status are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    Rome, 00168, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.